Coxsackievirus and adenovirus receptor promotes antitumor activity of oncolytic adenovirus H101 in esophageal cancer

International Journal of Molecular Medicine

Volumn 30, Issue 6, 2012, Pages 1403-1409

  Ma, Junfen ^a   Zhao, Jimin ^a   Lu, Jing ^a   Jiang, Yanan ^a   Yang, Hongyan ^a   Li, Pei ^a   Zhao, Mingyao ^a   Liu, Kangdong ^a   Dong, Ziming ^a  

^a ZHENGZHOU UNIVERSITY   (China)

Author keywords

Coxsackievirus and adenovirus receptor; Esophageal cancer; Extracellular regulated protein kinases; Trichostatin A

Indexed keywords

COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 3; ONCOLYTIC ADENOVIRUS; ONCOLYTIC ADENOVIRUS H101; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOMA CELL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FLOW CYTOMETRY; HELA CELL; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR CELL DESTRUCTION; WESTERN BLOTTING;

ADENOVIRIDAE; CARCINOMA, SQUAMOUS CELL; CELL SURVIVAL; COXSACKIE AND ADENOVIRUS RECEPTOR-LIKE MEMBRANE PROTEIN; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION; HELA CELLS; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MAP KINASE SIGNALING SYSTEM; ONCOLYTIC VIRUSES; TRANSCRIPTIONAL ACTIVATION; VIRUS INTERNALIZATION; VIRUS REPLICATION;

EID: 84869455158     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2012.1133     Document Type: Article

References (33)

1. Shigemitsu K, Naomoto Y, Shirakawa Y, Haisa M, Gunduz M and Tanaka N: A case of advanced esophageal cancer with extensive lymph node metastases successfully treated with multimodal therapy. Jpn J Clin Oncol 32: 310-314, 2002. (Pubitemid 43102801)
2. Baxi SH, Burmeister B, Harvey JA, Smithers M and Thomas J: Salvage definitive chemo-radiotherapy for locally recurrent oesophageal carcinoma after primary surgery: retrospective review. J Med Imaging Radiat Oncol 52: 583-587, 2008.
3. Hartwig W, Strobel O, Lordick F, Buchler MW and Werner J: Multimodal therapy of esophageal cancer. Z Gastroenterol 46: 1207-1213, 2008 (In German).
4. Guo W and Jiang YG: Current gene expression studies in esophageal carcinoma. Curr Genomics 10: 534-539, 2009.
5. Lin CC and Papadopoulos KP: Novel targeted therapies for advanced esophageal cancer. Dis Esophagus 20: 365-371, 2007. (Pubitemid 47323674)
6. Tew WP, Kelsen DP and Ilson DH: Targeted therapies for esophageal cancer. Oncologist 10: 590-601, 2005. (Pubitemid 41429122)
7. Nettelbeck DM, Jerome V and Muller R: Gene therapy: designer promoters for tumour targeting. Trends Genet 16: 174-181, 2000. (Pubitemid 30169153)
8. Ko D, Hawkins L and Yu DC: Development of transcriptionally regulated oncolytic adenoviruses. Oncogene 24: 7763-7774, 2005. (Pubitemid 41670678)
9. Lichtenstein DL and Wold WS: Experimental infections of humans with wild-type adenoviruses and with replication-competent adenovirus vectors: replication, safety, and transmission. Cancer Gene Ther 11: 819-829, 2004. (Pubitemid 39636349)
10. Jiang H, Gomez-Manzano C, Lang FF, Alemany R and Fueyo J: Oncolytic adenovirus: preclinical and clinical studies in patients with human malignant gliomas. Curr Gene Ther 9: 422-427, 2009.
11. Walters RW, Freimuth P, Moninger TO, Ganske I, Zabner J and Welsh MJ: Adenovirus fiber disrupts CAR-mediated intercellular adhesion allowing virus escape. Cell 110: 789-799, 2002. (Pubitemid 35283966)
12. Pandha HS, Stockwin LH, Eaton J, et al: Coxsackie B and adenovirus receptor, integrin and major histocompatibility complex class I expression in human prostate cancer cell lines: implications for gene therapy strategies. Prostate Cancer Prostatic Dis 6: 6-11, 2003. (Pubitemid 36432614)
13. Abdolazimi Y, Mojarrad M, Pedram M and Modarressi MH: Analysis of the expression of coxsackievirus and adenovirus receptor in five colon cancer cell lines. World J Gastroenterol 13: 6365-6369, 2007.
14. Yamashita M, Ino A, Kawabata K, Sakurai F and Mizuguchi H: Expression of coxsackie and adenovirus receptor reduces the lung metastatic potential of murine tumor cells. Int J Cancer 121: 1690-1696, 2007. (Pubitemid 47417284)
15. Wang Y, Thorne S, Hannock J, et al: A novel assay to assess primary human cancer infectibility by replication-selective oncolytic adenoviruses. Clin Cancer Res 11: 351-360, 2005. (Pubitemid 40075815)
16. Anders M, Vieth M, Rocken C, et al: Loss of the coxsackie and adenovirus receptor contributes to gastric cancer progression. Br J Cancer 100: 352-359, 2009.
17. Lee JH and Marks PA: Histone deacetylase inhibitors in the therapy of cancer: much to learn. Epigenomics 2: 723-725, 2010.
18. Kitazono M, Goldsmith ME, Aikou T, Bates S and Fojo T: Enhanced adenovirus transgene expression in malignant cells treated with the histone deacetylase inhibitor FR901228. Cancer Res 61: 6328-6330, 2001. (Pubitemid 32783231)
19. Segura-Pacheco B, Avalos B, Rangel E, Velazquez D and Cabrera G: HDAC inhibitor valproic acid upregulates CAR in vitro and in vivo. Genet Vaccines Ther 5: 10, 2007.
20. Somech R, Izraeli S and J Simon A: Histone deacetylase inhibitors - a new tool to treat cancer. Cancer Treat Rev 30: 461-472, 2004.
21. Ramos JW: The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells. Int J Biochem Cell Biol 40: 2707-2719, 2008.
22. Benedict CA, Norris PS, Prigozy TI, et al: Three adenovirus E3 proteins cooperate to evade apoptosis by tumor necrosis factor-related apoptosis-inducing ligand receptor-1 and -2. J Biol Chem 276: 3270-3278, 2001.
23. Lu W, Zheng S, Li XF, Huang JJ, Zheng X and Li Z: Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: a pilot phase II clinical trial. World J Gastroenterol 10: 3634-3638, 2004. (Pubitemid 39619282)
24. Toth K and Wold WS: Increasing the efficacy of oncolytic adenovirus vectors. Viruses 2: 1844-1866, 2010.
25. He Q, Liu Y, Zou Q and Guan YS: Transarterial injection of H101 in combination with chemoembolization overcomes recurrent hepatocellular carcinoma. World J Gastroenterol 17: 2353-2355, 2011.
26. Marchion D and Munster P: Development of histone deacetylase inhibitors for cancer treatment. Expert Rev Anticancer Ther 7: 583-598, 2007. (Pubitemid 46690964)
27. Weichert W: HDAC expression and clinical prognosis in human malignancies. Cancer Lett 280: 168-176, 2009.
28. Chen G, Wang BB, Li FJ, et al: Enhancive effect of histone deacetylase inhibitor trichostatin a on transfection efficiency of adenovirus in ovarian carcinoma cell line A2780. Ai Zheng 24: 1196-1200, 2005 (In Chinese).
29. Pong RC, Lai YJ, Chen H, et al: Epigenetic regulation of coxsackie and adenovirus receptor (CAR) gene promoter in urogenital cancer cells. Cancer Res 63: 8680-8686, 2003. (Pubitemid 38064044)
30. McCubrey JA, Steelman LS, Chappell WH, et al: Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773: 1263-1284, 2007. (Pubitemid 47125967)
31. Boldt S, Weidle UH and Kolch W: The kinase domain of MEKK1 induces apoptosis by dysregulation of MAP kinase pathways. Exp Cell Res 283: 80-90, 2003. (Pubitemid 36259897)
32. Anders M, Christian C, McMahon M, McCormick F and Korn WM: Inhibition of the Raf/MEK/ERK pathway up-regulates expression of the coxsackievirus and adenovirus receptor in cancer cells. Cancer Res 63: 2088-2095, 2003. (Pubitemid 36538611)
33. Bagheri N, Shiina M, Lauffenburger DA and Korn WM: A dynamical systems model for combinatorial cancer therapy enhances oncolytic adenovirus efficacy by MEK-inhibition. PLoS Comput Biol 7: e1001085, 2011.